+

PL1761266T3 - Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry - Google Patents

Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry

Info

Publication number
PL1761266T3
PL1761266T3 PL05754754T PL05754754T PL1761266T3 PL 1761266 T3 PL1761266 T3 PL 1761266T3 PL 05754754 T PL05754754 T PL 05754754T PL 05754754 T PL05754754 T PL 05754754T PL 1761266 T3 PL1761266 T3 PL 1761266T3
Authority
PL
Poland
Prior art keywords
formulations
treating
compounds
methods
skin disorders
Prior art date
Application number
PL05754754T
Other languages
English (en)
Inventor
Jack A Dejovin
Thomas M Rossi
Original Assignee
Galderma Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa
Publication of PL1761266T3 publication Critical patent/PL1761266T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL05754754T 2004-05-25 2005-05-25 Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry PL1761266T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
EP05754754.9A EP1761266B1 (en) 2004-05-25 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
PCT/US2005/018288 WO2005115395A2 (en) 2004-05-25 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Publications (1)

Publication Number Publication Date
PL1761266T3 true PL1761266T3 (pl) 2013-09-30

Family

ID=35451386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05754754T PL1761266T3 (pl) 2004-05-25 2005-05-25 Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry

Country Status (15)

Country Link
EP (2) EP1761266B1 (pl)
JP (2) JP4955543B2 (pl)
KR (1) KR101257046B1 (pl)
CN (2) CN104490884A (pl)
AU (1) AU2005247467B2 (pl)
BR (1) BRPI0511519A (pl)
CA (2) CA2567401C (pl)
DK (1) DK1761266T3 (pl)
ES (2) ES2424644T3 (pl)
MX (1) MXPA06013649A (pl)
NZ (1) NZ552325A (pl)
PL (1) PL1761266T3 (pl)
PT (1) PT1761266E (pl)
SI (1) SI1761266T1 (pl)
WO (1) WO2005115395A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117377A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
JP5747392B2 (ja) * 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
MX354697B (es) * 2010-10-21 2018-03-15 Galderma Sa Composiciones de gel de brimonidina y métodos de uso.
KR20130101552A (ko) * 2010-10-21 2013-09-13 갈데르마 소시에떼아노님 국소용 겔 조성물
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
DK3093017T3 (da) * 2010-11-16 2021-04-06 Allergan Inc Farmaceutisk sammensætning omfattende (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol til behandling af optisk neuropati
ES2742273T3 (es) 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
AU2012324543B2 (en) * 2011-10-19 2017-08-10 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
BR112015027984A2 (pt) * 2013-05-06 2017-09-05 Allergan Inc Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
KR20160055794A (ko) * 2013-07-26 2016-05-18 갈데르마 리서치 & 디벨로프먼트 피부 비후의 치료용 조성물
WO2015054058A1 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Dexmedetomidine Transdermal Delivery Devices and Methods for Using the Same
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
EP3319607A4 (en) * 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
US20220218590A1 (en) * 2019-05-14 2022-07-14 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
HUP0101469A3 (en) * 1997-11-24 2003-01-28 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (pl) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
KR100757656B1 (ko) * 2000-07-14 2007-09-10 알레간 인코포레이티드 알파 2-아드레날린 작용제 성분을 함유하는 조성물
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
EP2481412B1 (en) 2017-09-27
ES2647618T3 (es) 2017-12-22
CA2824612C (en) 2016-08-16
JP2008500356A (ja) 2008-01-10
PT1761266E (pt) 2013-06-04
AU2005247467A1 (en) 2005-12-08
WO2005115395A2 (en) 2005-12-08
CA2824612A1 (en) 2005-12-08
EP1761266A4 (en) 2009-11-11
CA2567401A1 (en) 2005-12-08
SI1761266T1 (sl) 2013-08-30
NZ552325A (en) 2010-11-26
DK1761266T3 (da) 2013-08-05
JP4955543B2 (ja) 2012-06-20
AU2005247467B2 (en) 2010-12-02
EP2481412A1 (en) 2012-08-01
CN104490884A (zh) 2015-04-08
MXPA06013649A (es) 2007-07-09
JP2012072176A (ja) 2012-04-12
EP1761266A2 (en) 2007-03-14
CN101426502A (zh) 2009-05-06
CA2567401C (en) 2013-11-12
EP1761266B1 (en) 2013-05-08
JP5547705B2 (ja) 2014-07-16
ES2424644T3 (es) 2013-10-07
BRPI0511519A (pt) 2007-12-26
KR20070032716A (ko) 2007-03-22
KR101257046B1 (ko) 2013-04-22
WO2005115395A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
PL1761266T3 (pl) Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
GB2423928B (en) Methods and compositions for treating pain
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL180187A0 (en) Compositions and methods for treating inflammatory disorders
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
HK1101140A1 (en) Compositions and methods for treating neurological disorders
EP1959929A4 (en) COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
EP1959931A4 (en) COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN
IL186963A0 (en) Methods and compositions for treating pain
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
HK1214158A1 (zh) 治療澱粉樣變性的製劑和方法
WO2006121421A8 (en) Methods and formulations for treating glaucoma
EP1841397A4 (en) TRICHOLOGY FORMULATIONS AND TREATMENTS
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
IL187405A0 (en) Methods and compositions for the treatment of pain
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
EP1755637B8 (en) Methods for preventing or treating bone disorders
ZA200710476B (en) Methods and compositions for the treatment of pain
EP1718329A4 (en) METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders
AU2004902388A0 (en) Methods for preventing or treating bone disorders
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载